Accelrys and Agilent Technologies Enter into Comprehensive Resale Agreement
News Oct 03, 2007
Accelrys Inc. and Agilent Technologies Inc. announced they have entered into a comprehensive resale agreement to enable the licensing and integration of their informatics products. The partnership covers the breadth of informatics portfolios of both companies and will enable customers in the pharmaceutical industry to enjoy unprecedented integration of laboratory data, experimental results and insights across the enterprise.
“This partnership will enable unparalleled integration of informatics products,” said Bruce von Herrmann, Agilent vice president and general manager, Informatics Division. “It will significantly benefit pharmaceutical companies that want to spend less time integrating existing informatics solutions and more time developing new, more effective medicines.”
Agilent and Accelrys will offer compatible and enhanced solutions incorporating their respective portfolios of informatics products. Accelrys will resell OpenLAB Enterprise Content Manager, Kalabie Electronic Lab Notebook, and GeneSpring gene expression solutions. Agilent will resell Accord cheminformatics solutions and Pipeline Pilot Scientific Operating Platform solutions.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.